Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134273 · ClinicalTrials.gov registry record · Phase 1
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,260
- Enrollment target
NCT04134273: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT04134273 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,260 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2000% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04134273, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,260 participants
- Enrollment target
Study Summary
This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
Primary Outcome
Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts.
Interventions
- DRUG Placebo
- DRUG Clindamycin
- DRUG CLPG Topical Gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,260 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 1 |
What the finished NCT04134273 record still lists
NCT04134273 is an interventional study that assigns participants to a tested intervention. Its 1,260 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2000% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04134273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04134273 about?
NCT04134273 is a clinical study titled "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris". This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.
What is the current status of trial NCT04134273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,260 participants. The study started on 2019-03-20. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT04134273?
The interventions under investigation include: Placebo (DRUG), Clindamycin (DRUG), CLPG Topical Gel 1% (DRUG).
Who is sponsoring clinical trial NCT04134273?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04134273's enrollment target sits among peer trials
1,260 5th of 2000 higher than 1,996 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI